<DOC>
	<DOC>NCT02315066</DOC>
	<brief_summary>To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.</brief_summary>
	<brief_title>Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Diagnosis of hepatocellular carcinoma (HCC) (Parts A1 and A2), melanoma (Parts A1 and B1), clear cell renal cell carcinoma (RCC) (Part A1), head and neck squamous cell carcinoma (HNSCC) (Parts B1 and B2), non small cell lung cancer (NSCLC) (Parts B1 and B2), urothelial bladder carcinoma (Part B1), gastric or squamous cell carcinoma of the uterine cervix (Part B1) who progressed on or are intolerant to standard therapy, for which no standard therapy is available or who decline standard therapy. Performance Status of 0 or 1 Adequate bone marrow, kidney and liver function Brain metastases requiring steroids Major surgery, radiation therapy, or systemic anticancer therapy within 4 weeks of study treatment start (6 weeks for mitomycin C or nitrosoureas) Active and clinically significant bacterial, fungal, or viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>PF-04518600</keyword>
	<keyword>PF-05082566</keyword>
	<keyword>solid tumors</keyword>
	<keyword>tumors</keyword>
	<keyword>neoplasm metastasis</keyword>
	<keyword>Phase 1</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>Liver cancer</keyword>
	<keyword>melanoma</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>RCC</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>head and neck squamous cell carcinoma</keyword>
	<keyword>HNSCC</keyword>
	<keyword>head and neck cancer</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>cancer of the cervix</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>stomach cancer</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>lung cancer</keyword>
	<keyword>urothelial bladder carcinoma</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>OX40</keyword>
	<keyword>4-1BB</keyword>
</DOC>